{"id":238482,"date":"2026-09-09T15:24:46","date_gmt":"2026-09-09T09:54:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=238482"},"modified":"2026-09-09T15:24:46","modified_gmt":"2026-09-09T09:54:46","slug":"bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Bafna Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Bafna Pharmaceuticals share price Rs 301.60 on 9 September 2026, down 2.00%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 0.08 crore. Q2 FY26 base a profit of Rs 3.12 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Bafna Pharmaceuticals Q2 results date for FY27 is not confirmed, and Bafna Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 35.47 crore in revenue and a profit of Rs 3.12 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Bafna Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/bafnaph\/bafna-pharmaceuticals-ltd-share-price-today\">Bafna Pharmaceuticals Ltd.<\/a>, a contract and own-brand manufacturer of finished pharmaceutical formulations, mainly oral solids and liquids, selling domestically and into registered export markets. The stock traded at Rs 301.60 on the NSE on 9 September 2026, down 2.00% from the previous close of Rs 307.75, about 5.3% below its 52-week high of Rs 318.50 and 218.2% above its 52-week low of Rs 94.77.<\/p>\n<p>What makes the Bafna Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 35.47 crore of revenue and a profit of Rs 3.12 crore, while the most recent quarter on record, Q1 FY27, produced Rs 26.58 crore and a profit of Rs 0.08 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=bafnaph_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#When_Is_the_Bafna_Pharmaceuticals_Q2_Results_FY27_Date\" title=\"When Is the Bafna Pharmaceuticals Q2 Results FY27 Date?\">When Is the Bafna Pharmaceuticals Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Bafna_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Bafna Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking\">Bafna Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Bafna_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Bafna Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Bafna Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Bafna_Pharmaceuticals_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Bafna Pharmaceuticals Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Bafna Pharmaceuticals Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Bafna_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Bafna Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters\">Bafna Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Bafna_Pharmaceuticals_Q2_Results_FY27\" title=\"Key Factors That Could Shape Bafna Pharmaceuticals Q2 Results FY27\">Key Factors That Could Shape Bafna Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Capacity_Utilisation_in_Formulations\" title=\"Capacity Utilisation in Formulations\">Capacity Utilisation in Formulations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Other_Income_Now_Exceeds_Operating_Profit\" title=\"Other Income Now Exceeds Operating Profit\">Other Income Now Exceeds Operating Profit<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Stock_Has_Tripled_Off_a_Low_Base\" title=\"Stock Has Tripled Off a Low Base\">Stock Has Tripled Off a Low Base<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Bafna_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Bafna Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print\">Bafna Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Bafna_Pharmaceuticals_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Bafna Pharmaceuticals Q2 Results Are Announced\">What Investors Should Watch When Bafna Pharmaceuticals Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Bafna_Pharmaceuticals_Q2_Results_FY27\" title=\"Conclusion on Bafna Pharmaceuticals Q2 Results FY27\">Conclusion on Bafna Pharmaceuticals Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#FAQs_on_Bafna_Pharmaceuticals_Q2_Results_FY27\" title=\"FAQs on Bafna Pharmaceuticals Q2 Results FY27\">FAQs on Bafna Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_the_Bafna_Pharmaceuticals_Q2_results_date_for_FY27\" title=\"What is the Bafna Pharmaceuticals Q2 results date for FY27?\">What is the Bafna Pharmaceuticals Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Bafna_Pharmaceuticals_Q2_results_2026_cover\" title=\"What quarter do the Bafna Pharmaceuticals Q2 results 2026 cover?\">What quarter do the Bafna Pharmaceuticals Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_the_Bafna_Pharmaceuticals_Q1_FY27_results\" title=\"What were the Bafna Pharmaceuticals Q1 FY27 results?\">What were the Bafna Pharmaceuticals Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_Bafna_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Bafna Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\">What were Bafna Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Bafna_Pharmaceuticals_Q2_results_expectations_this_quarter\" title=\"What are the main Bafna Pharmaceuticals Q2 results expectations this quarter?\">What are the main Bafna Pharmaceuticals Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_Bafna_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Bafna Pharmaceuticals share price today ahead of the Q2 earnings?\">What is Bafna Pharmaceuticals share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Is_Bafna_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Bafna Pharmaceuticals a good stock to buy before the Q2 results?\">Is Bafna Pharmaceuticals a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Bafna_Pharmaceuticals_Q2_Results_FY27_Date\"><\/span><strong>When Is the Bafna Pharmaceuticals Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Bafna Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 9 September 2026, Bafna Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Bafna Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Bafna Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Bafna Pharmaceuticals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bafna_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Bafna Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Bafna Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Bafna Pharmaceuticals. The Bafna Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>The first is the collapse in Q1 FY27. Revenue fell to Rs 26.58 crore from Rs 42.24 crore, the operating margin to 3.35% from 8.40%, and operating profit to Rs 0.89 crore. That is the weakest quarter in the visible record.<\/p>\n<p>The second is that the margin has fallen steadily rather than in one step. It ran 14.64%, 12.07%, 7.97%, 8.40% and 3.35% across the five quarters, so the September 2025 base of 12.07% is a long way above the current level.<\/p>\n<p>The third is that reported profit is untaxed. The effective rate was zero in four of the five quarters and negative in the fifth, reflecting carried-forward losses from the company&#8217;s earlier insolvency, so profit is not comparable to a normal taxpayer.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Bafna Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bafna_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Bafna Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bafna Pharmaceuticals Ltd. reported revenue of Rs 26.58 crore in Q1 FY27, down 23.22% from Rs 34.62 crore in Q1 FY26, and a profit of Rs 0.08 crore at the net level, down 97.64% from Rs 3.39 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was down 37.07% over the March 2026 quarter figure of Rs 42.24 crore, and net profit was down 97.09% from Rs 2.75 crore in Q4 FY26. Operating margin stood at 3.35% in Q1 FY27 against 12.07% in the September 2025 quarter, which is the comparison the Bafna Pharmaceuticals Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Bafna_Pharmaceuticals_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Bafna Pharmaceuticals Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bafna Pharmaceuticals Ltd. reported revenue of Rs 35.47 crore and a profit of Rs 3.12 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Bafna Pharmaceuticals Q2 results preview.<\/p>\n<p>Net profit in that base quarter was above the Rs 0.08 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 35.47 crore sits above the Rs 26.58 crore of the June 2026 quarter, which frames how much sequential movement the Bafna Pharmaceuticals Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bafna_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Bafna Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>35.47<\/td>\n<td>3.12<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>38.29<\/td>\n<td>1.84<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>42.24<\/td>\n<td>2.75<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>26.58<\/td>\n<td>0.08<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Bafna Pharmaceuticals Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 26.58 crore to Rs 42.24 crore, and net profit from Rs 0.08 crore to Rs 3.12 crore. That spread is the honest context for the Bafna Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Bafna_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Bafna Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Bafna Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Bafna Pharmaceuticals has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Capacity_Utilisation_in_Formulations\"><\/span><strong>Capacity Utilisation in Formulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Oral solid dosage plants carry a largely fixed cost base, so how full the lines run decides margin more than product pricing does. A revenue fall of a third in one quarter compresses margin sharply.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Other_Income_Now_Exceeds_Operating_Profit\"><\/span><strong>Other Income Now Exceeds Operating Profit<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Other income rose from Rs 0.60 crore to Rs 1.91 crore over the five quarters while operating profit fell from Rs 5.07 crore to Rs 0.89 crore. In Q1 FY27 it was more than double the operating result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Stock_Has_Tripled_Off_a_Low_Base\"><\/span><strong>Stock Has Tripled Off a Low Base<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The shares trade at Rs 301.60 against a 52-week low of Rs 94.77 with a 14-day RSI of 77.57, at a price-to-earnings ratio of 91.46 and 7.43 times a book value of Rs 40.60.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bafna_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Bafna Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bafna Pharmaceuticals share price today is Rs 301.60 on the NSE, down Rs 6.15 or 2.00% from the previous close of Rs 307.75 on 9 September 2026, ahead of the Bafna Pharmaceuticals Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (9 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>BAFNAPH<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 301.60<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 318.50<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 94.77<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 712.52 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>91.46<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>7.43<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 3.30<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 40.60<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.39<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>12.30%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 255.17<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 166.25<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>77.57<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 255.17 and its 200-day average of Rs 166.25, with a 14-day RSI of 77.57. None of this is a view on where the shares go once the Bafna Pharmaceuticals Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Bafna Pharmaceuticals Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Bafna_Pharmaceuticals_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Bafna Pharmaceuticals Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Bafna Pharmaceuticals Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 35.47 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 3.12 crore in that same quarter<\/li>\n<li>Operating margin against 3.35% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Bafna Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Bafna_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Conclusion on Bafna Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Bafna Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Bafna Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Bafna Pharmaceuticals Q2 results FY27 print faces a base of Rs 35.47 crore in revenue and a profit of Rs 3.12 crore, with the most recent quarter having delivered Rs 26.58 crore and a profit of Rs 0.08 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Bafna Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Bafna_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>FAQs on Bafna Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bafna_Pharmaceuticals_Q2_results_date_for_FY27\"><\/span><strong>What is the Bafna Pharmaceuticals Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Bafna Pharmaceuticals Q2 results date for FY27 is not confirmed. Bafna Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Bafna_Pharmaceuticals_Q2_results_2026_cover\"><\/span><strong>What quarter do the Bafna Pharmaceuticals Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Bafna Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Bafna Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Bafna Pharmaceuticals Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Bafna_Pharmaceuticals_Q1_FY27_results\"><\/span><strong>What were the Bafna Pharmaceuticals Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bafna Pharmaceuticals Ltd. reported revenue of Rs 26.58 crore in Q1 FY27 and a profit of Rs 0.08 crore at the net level. Revenue was down 23.22% versus Q1 FY26 and net profit was down 97.64% from Rs 3.39 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Bafna_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Bafna Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bafna Pharmaceuticals Ltd. reported revenue of Rs 35.47 crore and a profit of Rs 3.12 crore in Q2 FY26. Operating margin was 12.07%. Those figures form the base for the Bafna Pharmaceuticals Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Bafna_Pharmaceuticals_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Bafna Pharmaceuticals Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Bafna Pharmaceuticals Q2 results expectations centre on revenue against the Rs 35.47 crore base, net profit against a profit of Rs 3.12 crore, operating margin against 3.35% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Bafna_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Bafna Pharmaceuticals share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bafna Pharmaceuticals share price is Rs 301.60 on the NSE as of 9 September 2026, down 2.00% from Rs 307.75. The stock is about 5.3% below its 52-week high of Rs 318.50 and 218.2% above its 52-week low of Rs 94.77, at a market capitalisation of Rs 712.52 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Bafna_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Bafna Pharmaceuticals a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Bafna Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 7.43 with a return on equity of 12.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Bafna Pharmaceuticals Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Bafna Pharmaceuticals Q2 results date for FY27 is not confirmed. Bafna Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Bafna Pharmaceuticals Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Bafna Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Bafna Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Bafna Pharmaceuticals Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Bafna Pharmaceuticals Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Bafna Pharmaceuticals Ltd. reported revenue of Rs 26.58 crore in Q1 FY27 and a profit of Rs 0.08 crore at the net level. Revenue was down 23.22% versus Q1 FY26 and net profit was down 97.64% from Rs 3.39 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Bafna Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Bafna Pharmaceuticals Ltd. reported revenue of Rs 35.47 crore and a profit of Rs 3.12 crore in Q2 FY26. Operating margin was 12.07%. Those figures form the base for the Bafna Pharmaceuticals Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Bafna Pharmaceuticals Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Bafna Pharmaceuticals Q2 results expectations centre on revenue against the Rs 35.47 crore base, net profit against a profit of Rs 3.12 crore, operating margin against 3.35% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Bafna Pharmaceuticals share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Bafna Pharmaceuticals share price is Rs 301.60 on the NSE as of 9 September 2026, down 2.00% from Rs 307.75. The stock is about 5.3% below its 52-week high of Rs 318.50 and 218.2% above its 52-week low of Rs 94.77, at a market capitalisation of Rs 712.52 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Bafna Pharmaceuticals a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Bafna Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 7.43 with a return on equity of 12.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bafna Pharmaceuticals Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Bafna Pharmaceuticals Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":238480,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-238482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["238480"],"rank_math_title":["Bafna Pharmaceuticals Q2 FY27: Date and Outlook"],"rank_math_description":["Bafna Pharmaceuticals Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Bafna Pharmaceuticals Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/bafna-pharmaceuticals-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/238482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=238482"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/238482\/revisions"}],"predecessor-version":[{"id":238483,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/238482\/revisions\/238483"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/238480"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=238482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=238482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=238482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}